Literature DB >> 22497966

Healthcare-associated vs. hospital-acquired Staphylococcus aureus bacteremia.

Jihad Bishara1, Elad Goldberg, Leonard Leibovici, Zmira Samra, Hila Shaked, Nariman Mansur, Mical Paul.   

Abstract

OBJECTIVE: To analyze clinical features and outcomes of patients with hospital-acquired (HA) and healthcare-associated (HCA) Staphylococcus aureus bacteremia.
METHODS: A retrospective cohort study was conducted from 1988 to 2007. We compared patients with clinically significant HA with those with HCA S. aureus bacteremia. Risk factors for 30-day all-cause mortality were assessed using multivariable logistic regression analysis. Cox regression analysis was used to estimate the hazard ratio (HR) for 5-year mortality with 95% confidence intervals (CI).
RESULTS: Of 1261 episodes, 735 (58.3%) were HA and 526 (41.7%) were HCA. The percentage of MRSA was 48.2% (354/735) in HA vs. 42.2% (222/526) in HCA bacteremia; p=0.04. The percentages of HCA S. aureus bacteremia and MRSA bacteremia did not vary throughout the study period. Mortality at 30 days was 40.2% (507/1261) and at 1 year was 63.4% (800/1261); this was comparable for HA and HCA bacteremia. Five-year survival curves in both settings followed very similar patterns (HR 1.01, 95% CI 0.89-1.15). Risk factors for 30-day mortality were similar, except for primary bacteremia and pre-existing heart valve disease in the HA group.
CONCLUSIONS: HCA S. aureus bacteremia shares many similarities with HA bacteremia with respect to the prevalence of MRSA strains, mortality rates, and risk factors for death, and should be managed similarly.
Copyright © 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22497966     DOI: 10.1016/j.ijid.2012.02.009

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  8 in total

1.  Thrombocytopaenia during methicillin-sensitive Staphylococcus aureus bacteraemia.

Authors:  E Forsblom; I Tielinen; E Ruotsalainen; A Järvinen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-12-23       Impact factor: 3.267

Review 2.  Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.

Authors:  Steven Y C Tong; Joshua S Davis; Emily Eichenberger; Thomas L Holland; Vance G Fowler
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

3.  Methicillin and Vancomycin Resistant Staphylococcus aureus and Associated Factors from Surgical Ward Inpatients at Debre Markos Referral Hospital, Northwest Ethiopia.

Authors:  Samrawit Tefera; Tewachew Awoke; Daniel Mekonnen
Journal:  Infect Drug Resist       Date:  2021-08-10       Impact factor: 4.003

Review 4.  Exploration of Modulated Genetic Circuits Governing Virulence Determinants in Staphylococcus aureus.

Authors:  Rekha Arya; S Adline Princy
Journal:  Indian J Microbiol       Date:  2015-10-22       Impact factor: 2.461

5.  Ability of biofilm production and molecular analysis of spa and ica genes among clinical isolates of methicillin-resistant Staphylococcus aureus.

Authors:  Mitra Omidi; Farzaneh Firoozeh; Mahmood Saffari; Hossein Sedaghat; Mohammad Zibaei; Azad Khaledi
Journal:  BMC Res Notes       Date:  2020-01-07

6.  Clinical Characteristics and Outcomes of S. Aureus Bacteremia in Patients Receiving Total Parenteral Nutrition.

Authors:  Michelle Gompelman; Renée A M Tuinte; Marvin A H Berrevoets; Chantal P Bleeker-Rovers; Geert J A Wanten
Journal:  Nutrients       Date:  2020-10-14       Impact factor: 5.717

7.  Human Urine Alters Methicillin-Resistant Staphylococcus aureus Virulence and Transcriptome.

Authors:  Santosh Paudel; Kamal Bagale; Swapnil Patel; Nicholas J Kooyers; Ritwij Kulkarni
Journal:  Appl Environ Microbiol       Date:  2021-07-27       Impact factor: 4.792

Review 8.  A review of infection control in community healthcare: new challenges but old foes.

Authors:  W G Mackay; K Smith; C Williams; C Chalmers; R Masterton
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-07-04       Impact factor: 3.267

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.